Blockchain Registration Transaction Record

Annovis Bio Announces Public Offering to Fund Alzheimer's Trial

Annovis Bio (NYSE: ANVS) announces a public offering to fund Phase 3 trials of buntanetap for Alzheimer's and Parkinson's diseases. Learn about the company's innovative approach targeting multiple neurotoxic proteins.

This news matters because Alzheimer's and Parkinson's diseases affect over 50 million people globally, with limited effective treatments. Annovis's buntanetap targets multiple neurotoxic proteins, offering a potential disease-modifying therapy that could slow or halt progression. The public offering is a critical step to fund Phase 3 trials, bringing us closer to a new treatment option that could improve the lives of patients and their families.